Entering text into the input field will update the search result below

Onconova (+14%) advancing late-stage study of rigosertib in MDS

  • Onconova Therapeutics (ONTX +14.2%) announces that the required number of survival events has been reached in its Phase 3 clinical trial, INSPIRE, evaluating rigosertib in myelodysplastic syndromes (MDS) patients who failed to respond to chemotherapy.
  • Topline data should be available by the end of September.
  • Rigosertib is a small molecule that inhibits cellular signaling by acting as a Ras protein mimetic. Ras is a family of proteins that is involved in transmitting signals within cells. When switched "on", it activates other proteins that ultimately turn on genes involved in cell growth, differentiation and survival.
  • MDS are a group of blood cancers in which immature blood cells in the bone marrow fail to mature into healthy blood cells.
  • "Onconova has enjoyed a significant appreciation in share value, but investors should tread carefully into the readout of INSPIRE and consider how the conflicting data around Rigosertib's MOA could potentially impact the overall value and potential of this drug," George Crist wrote on Seeking Alpha earlier today.

Recommended For You

About ONTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ONTX--
Onconova Therapeutics, Inc.